Patients with naproxen-induced liver injury display T-cell memory responses toward an oxidative (S)-O-desmethyl naproxen metabolite but not the acyl glucuronide.


Journal

Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028

Informations de publication

Date de publication:
Jan 2024
Historique:
revised: 30 05 2023
received: 24 03 2023
accepted: 13 06 2023
medline: 2 1 2024
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: ppublish

Résumé

Exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (IBU) and naproxen (NAP) is associated with idiosyncratic drug-induced liver injury (DILI). Carboxylate bioactivation into reactive metabolites (e.g., acyl glucuronides, AG) and resulting T-cell activation is hypothesized as causal for this adverse event. However, conclusive evidence supporting this is lacking. In this work, we identify CD4 CD4 Our results confirm hepatic T-cell infiltrations in NSAID-induced DILI, and show a T-cell memory response toward DM-NAP indicating an immune-mediated basis for the adverse event. Whilst bioactivation at the carboxylate group is widely hypothesized to be pathogenic for NSAID associated DILI, we found no evidence of this with NAP.

Sections du résumé

BACKGROUND BACKGROUND
Exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (IBU) and naproxen (NAP) is associated with idiosyncratic drug-induced liver injury (DILI). Carboxylate bioactivation into reactive metabolites (e.g., acyl glucuronides, AG) and resulting T-cell activation is hypothesized as causal for this adverse event. However, conclusive evidence supporting this is lacking.
METHODS METHODS
In this work, we identify CD4
RESULTS RESULTS
CD4
CONCLUSION CONCLUSIONS
Our results confirm hepatic T-cell infiltrations in NSAID-induced DILI, and show a T-cell memory response toward DM-NAP indicating an immune-mediated basis for the adverse event. Whilst bioactivation at the carboxylate group is widely hypothesized to be pathogenic for NSAID associated DILI, we found no evidence of this with NAP.

Identifiants

pubmed: 37515456
doi: 10.1111/all.15830
doi:

Substances chimiques

Naproxen 57Y76R9ATQ
Glucuronides 0
Anti-Inflammatory Agents, Non-Steroidal 0
Ibuprofen WK2XYI10QM

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

200-214

Subventions

Organisme : Medical Research Council
Pays : United Kingdom

Informations de copyright

© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Références

Br J Clin Pharmacol. 2005 Oct;60(4):423-33
pubmed: 16187975
Biochem Pharmacol. 1997 Jul 1;54(1):33-41
pubmed: 9296349
Hepatology. 2004 May;39(5):1430-40
pubmed: 15122773
Am J Pathol. 2014 Jun;184(6):1677-82
pubmed: 24731753
Chem Res Toxicol. 1998 Sep;11(9):969-88
pubmed: 9760271
Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):91-142
pubmed: 16922655
Nat Rev Rheumatol. 2011 Mar;7(3):139-50
pubmed: 21263458
J Med Chem. 2012 Nov 26;55(22):10136-47
pubmed: 23088558
Nat Genet. 2010 Aug;42(8):711-4
pubmed: 20639878
Toxicol Lett. 2017 Apr 15;272:1-7
pubmed: 28286018
J Pharm Sci. 1999 Jan;88(1):52-7
pubmed: 9874702
Drug Metab Rev. 1992;24(1):5-47
pubmed: 1555494
Hepatology. 2013 Feb;57(2):727-39
pubmed: 22987284
J Pharmacol Exp Ther. 2012 Jun;341(3):597-610
pubmed: 22371438
J Immunol. 2018 Mar 1;200(5):1952
pubmed: 29427419
Allergy. 2007 Dec;62(12):1439-44
pubmed: 17983378
J Pharmacol Exp Ther. 2014 Aug;350(2):387-402
pubmed: 24902585
Drug Metab Dispos. 1996 Oct;24(10):1050-7
pubmed: 8894504
Drug Metab Dispos. 1998 Mar;26(3):246-56
pubmed: 9492388
J Allergy Clin Immunol. 2012 Jun;129(6):1562-9.e5
pubmed: 22322005
Drug Metab Rev. 1984;15(5-6):1213-49
pubmed: 6396057
N Engl J Med. 2019 Apr 11;380(15):1483-1485
pubmed: 30970197
Life Sci. 1993;53(8):PL141-6
pubmed: 8350674
J Clin Invest. 1998 Oct 15;102(8):1591-8
pubmed: 9788973
Drug Metab Dispos. 2010 Oct;38(10):1857-64
pubmed: 20606003
Front Pharmacol. 2019 Jul 29;10:853
pubmed: 31417407
Allergy. 2024 Jan;79(1):200-214
pubmed: 37515456
Clin Gastroenterol Hepatol. 2005 May;3(5):489-98
pubmed: 15880319
Am J Transplant. 2009 Sep;9(9):2197-202
pubmed: 19706026
Drug Metab Dispos. 1982 Nov-Dec;10(6):609-13
pubmed: 6130909
J Immunol. 2013 May 15;190(10):4956-64
pubmed: 23596311
Rheumatology (Oxford). 2019 Jun 1;58(6):1099-1103
pubmed: 30715482
J Clin Invest. 1986 Mar;77(3):934-9
pubmed: 3949982
J Invest Dermatol. 2015 Sep;135(9):2237-2248
pubmed: 25946710
World Allergy Organ J. 2008 Jun;1(6):96-102
pubmed: 23282405
Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):817-28
pubmed: 21473713
Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):425-38
pubmed: 18433345
Biol Pharm Bull. 2013;36(9):1509-13
pubmed: 23832447
Aliment Pharmacol Ther. 2020 Mar;51(6):603-611
pubmed: 31984540
J Allergy Clin Immunol. 2006 Jul;118(1):233-41
pubmed: 16815161
Clin Gastroenterol Hepatol. 2018 Feb;16(2):292-294
pubmed: 28782674
Allergy. 2021 Jun;76(6):1825-1835
pubmed: 33150583
Br J Clin Pharmacol. 2005 Dec;60(6):632-40
pubmed: 16305588
Chem Res Toxicol. 2020 Jul 20;33(7):1551-1560
pubmed: 32525307
Allergy. 2018 Aug;73(8):1662-1672
pubmed: 29355985
Hepatology. 2015 Sep;62(3):887-99
pubmed: 25998949
Curr Med Res Opin. 1984;9(1):41-6
pubmed: 6373158
Arthritis Rheum. 1988 Mar;31(3):436-40
pubmed: 3358806
Clin Pharmacol Ther. 1983 Jul;34(1):97-103
pubmed: 6861443
J Pharmacokinet Biopharm. 1995 Aug;23(4):379-95
pubmed: 8882746
J Pharmacol Toxicol Methods. 1999 Feb;41(1):27-32
pubmed: 10507755
Nat Genet. 2009 Jul;41(7):816-9
pubmed: 19483685
J Biol Chem. 2019 Feb 1;294(5):1697-1705
pubmed: 30710016
Chem Res Toxicol. 1998 May;11(5):513-9
pubmed: 9585482
Toxicol Sci. 2017 Feb;155(2):420-431
pubmed: 27803386
J Biol Chem. 2010 Nov 5;285(45):34950-9
pubmed: 20810665
J Immunol. 2014 Apr 1;192(7):2984-93
pubmed: 24591375
Clin Liver Dis. 2007 Aug;11(3):563-75, vi-vii
pubmed: 17723920
Eur J Immunol. 1997 Jun;27(6):1303-7
pubmed: 9209477

Auteurs

Paul Thomson (P)

Molecular& Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Nik Fragkas (N)

Novartis Institutes for BioMedical Research, Basel, Switzerland.

Laila M Kafu (LM)

Molecular& Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Guruprasad P Aithal (GP)

NIHR Nottingham Biomedical Research Centre and Nottingham Digestive Diseases Centre, Translational Medical Sciences, West Block, Queen's Medical Centre, University of Nottingham, Nottingham, UK.

M Isabel Lucena (MI)

Unidad de Gestión Clínica de Aparato Digestivo y Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, CIBERehd, Malaga, Spain.

Luigi Terracciano (L)

Institute of Pathology, University Hospital Basel, Basel, Switzerland.

Xiaoli Meng (X)

Molecular& Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Munir Pirmohamed (M)

Molecular& Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Dominique Brees (D)

Novartis Institutes for BioMedical Research, Basel, Switzerland.

Gerd A Kullak-Ublick (GA)

University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Novartis Global Drug Development, Basel, Switzerland.

Alex Odermatt (A)

Division of Molecular & Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.

Thomas Hammond (T)

Division of Molecular & Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Oncology Safety, Clinical Pharmacology and Safety Sciences R&D, Cambridge, UK.

Michael Kammüller (M)

Novartis Institutes for BioMedical Research, Basel, Switzerland.

Dean J Naisbitt (DJ)

Molecular& Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH